74: Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions

Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), C. Lenahan(Beth Israel Deaconess Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Kathy D. Miller(Indiana University Health), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Zhiyou Wu(Dana-Farber Cancer Institute), Adam Bissonnette(Dana-Farber Cancer Institute), James D. Levine(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center)
Transplantation and Cellular Therapy
January 28, 2008
10.1016/j.bbmt.2007.12.082
Cited by 0

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k